Monday, May 27, 2024
HomeMedicalAnalyst Ratings For AVITA Medical

Analyst Ratings For AVITA Medical

AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you’ll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.0, a high estimate of $25.00, and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.52%.
Decoding Analyst Ratings: A Detailed Look
The standing of AVITA Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Matt O’Brien Piper Sandler Lowers Neutral $9.00 $21.00 Ross Osborn Cantor Fitzgerald Lowers Overweight $21.00 $22.00 Matt O’Brien Piper Sandler Raises Overweight $21.00 $19.00 Ross Osborn Cantor Fitzgerald Raises Overweight $25.00 $22.00
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they ‘Maintain’, ‘Raise’, or ‘Lower’ their stance, it signifies their response to recent developments related to AVITA Medical. This offers insight into analysts’ perspectives on the current state of the company.
Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they ‘Maintain’, ‘Raise’, or ‘Lower’ their stance, it signifies their response to recent developments related to AVITA Medical. This offers insight into analysts’ perspectives on the current state of the company. Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from ‘Outperform’ to ‘Underperform’. These ratings convey expectations for the relative performance of AVITA Medical compared to the broader market.
Analyzing trends, analysts offer qualitative evaluations, ranging from ‘Outperform’ to ‘Underperform’. These ratings convey expectations for the relative performance of AVITA Medical compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for AVITA Medical’s future value. Examining the current and prior targets offers insights into analysts’ evolving expectations.
Capture valuable insights into AVITA Medical’s market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on AVITA Medical analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About AVITA Medical
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It’s approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Unraveling the Financial Story of AVITA Medical
Market Capitalization Perspectives: The company’s market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: AVITA Medical’s revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 50.13%. This indicates a substantial increase in the company’s top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AVITA Medical’s net margin surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive -49.77% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company’s ROE is a standout performer, exceeding industry averages. With an impressive ROE of -12.61%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AVITA Medical’s ROA stands out, surpassing industry averages. With an impressive ROA of -7.33%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: AVITA Medical’s debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments

Translate »
×